ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment

Clinical Cancer Research

Volumn 22, Issue 7, 2016, Pages 1642-1652

  Lamberts, Laetitia E ^a   Menke Van Der Houven Van Oordt, Catharina W ^b   Ter Weele, Eva J ^a   Bensch, Frederike ^a   Smeenk, Michiel M ^a   Voortman, Johannes ^b   Hoekstra, Otto S ^b   Williams, Simon P ^c   Fine, Bernard M ^c   Maslyar, Daniel ^c   De Jong, Johan R ^a   Gietema, Jourik A ^a   Schröder, Carolien P ^a   Bongaerts, Alphons H H ^a   Lub De Hooge, Marjolijn N ^a   Verheul, Henk M W ^b   Sanabria Bohorquez, Sandra M ^c   Glaudemans, Andor W J M ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DMOT 4039A; MESOTHELIN; MMOT 0530A ZR 89; TRACER; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; ZIRCONIUM;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; FIRST IN HUMAN STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; ORGAN DISTRIBUTION; OVARY CANCER; PANCREAS CANCER; PET-CT SCANNER; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VOLUME OF DISTRIBUTION; IMMUNOLOGY; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROCEDURES; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ZIRCONIUM;

EID: 84964318513     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1272     Document Type: Article

References (53)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97.
3. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
4. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
5. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7:3862-8.
6. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
7. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45.
8. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-9.
9. Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 2014;20:1020-8.
10. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 2012;133:799-804.
11. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010;16:6132-8.
12. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res 2014;2:112.
13. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
14. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.
15. Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 2013;5: 208ra147.
16. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serummesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 2014;120:3311-9.
17. Bendell J, Blumenschein G, Zinner R, Hong D, Jones S, Infante J, et al. Firstin-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract nr LB-291.
18. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;19:1783-91.
19. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009;15:406-20.
20. de Vries EG, Oude Munnink TH, van Vugt MA, Nagengast WB. Toward molecular imaging-driven drug development in oncology. Cancer Discov 2011;1:25-8.
21. Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lub-de Hooge MN, Schroder CP, Gietema JA, et al. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol 2015;33: 1491-504.
22. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J 2008;14:191-7.
23. van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: Immuno-PET and TKI-PET. Tumour Biol 2012;33:607-15.
24. Borjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006; 12:2133-40.
25. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med 2013;54:1014-8.
26. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586-92.
27. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med 2015;56:63-9.
28. 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging 2012;39:512-20.
29. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
30. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010;21:5-13.
31. 89Zr-labeled anti-mesothelin antibody [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract nr 2659.
32. 89Zr-labeled chimericmonoclonal antibody U36as used for immuno-PET in head and neck cancer patients. J Nucl Med 2009;50:1828-36.
33. 89Zr-cetuximab. J Nucl Med 2015;56:249-54.
34. 89Zr-labeled monoclonal antibodies. J Nucl Med 2003;44: 1271-81.
35. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
36. Weekes C, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Robinson Diamond J, et al. A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum resistant ovarian cancer (OC). J Clin Oncol 32:5s, 2014 (suppl; abstr 2529).
37. Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther 2014;13:2630-40.
38. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2:131-7.
39. Oude Munnink TH, Dijkers EC, Netters SJ, Lub-de Hooge MN, Brouwers AH, Haasjes JG, et al. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J Clin Oncol 2010;28:355-7.
40. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005;56:361-9.
41. Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 2008;14:7981-6.
42. Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 2007;104:17099-104.
43. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2014;41: 2093-105.
44. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed bymultiregion sequencing. N Engl J Med 2012;366:883-92.
45. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer 1999;80:559-63.
46. 111Inlabeled MORAb-009, an anti-mesothelin antibody. Nucl Med Biol 2011;38:1119-27.
47. 111In labeled antibodies for SPECT imaging of mesothelin expressing tumors. Nucl Med Biol 2011;38:885-96.
48. 64Cu-labeled fab for detecting ERC/mesothelin in a mesothelioma mouse model. Nucl Med Commun 2010;31:380-8.
49. Ding H, Yong KT, Law WC, Roy I, Hu R, Wu F, et al. Non-invasive tumor detection in small animals using novel functional pluronic nanomicelles conjugated with anti-mesothelin antibody. Nanoscale 2011;3:1813-22.
50. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012;18:4266-76.
51. 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. Oncotarget 2015;6: 4496-504.
52. Ogasawara A, Flores F, Vanderbilt A, Tinianow JN, Gill H, Kan D, et al. Tumor uptake and efficacy of antibody drug conjugates using 89Zirconium Immuno PET. World Molecular Imaging Congress; 2011 Sept 7-10; San Diego, California: Abstract nr. P822.
53. 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2 positive breast cancer (mBC). J Clin Oncol 32:5s, 2014 (suppl; abstr 11001).